LemVega Capital

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. As a results-driven organization, we are constantly looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level.

The journey from discovery to medical breakthrough demands imagination, speed, and focus. At Mission BioCapital, we provide early-stage capital to the next generation of awesome life science entrepreneurs and the platform where they can realize their visions. This approach has revolutionized the way life science start-ups progress from idea to key data through a model that champions collaboration at the center of everything we do. Our team has a deep-rooted commitment to empowering exceptional life science entrepreneurs from all walks of life. From your first experiment in our shared lab space through to the clinic, we want to be your partner in accelerating development of scientific solutions – faster, focused and more efficiently – to individuals and communities in most need. We’re there, from idea to exit. We are scientists, investors, founders, and serial entrepreneurs. Our team has a long history together, investing in, launching, and building dozens of early-stage life science companies. Making Transformational Investments. Founded in 2009, we are now investing out of our fifth fund. Since our inception, we have invested in early-stage life science companies following the same core principles: Mentorship and Collaboration – within our team and with founders Innovation and Creativity – in how we structure our investments and find solutions to problems; we are entrepreneurs too! Respect and Support – for the founders we work with

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

Our expertise in biopharma and biotech investments. With decades of experience and a robust network within the biopharma and biotech industries, our team offers unparalleled insight into the scientific and financial landscapes. We are dedicated to identifying transformative therapies and supporting companies that are pioneering the future of healthcare. Empowering entrepeneurs to build leading companies Biovance Capital works closely with entrepreneurs to build leading companies with transformative treatments for patients in need. Stage: We invest in early-stage companies at seed and Series A rounds across Europe, with a focus in Southern countries. Technology: We invest in biotech companies developing therapeutics in any modality and therapeutic area. We require robust and appropriate preclinical models and patented or patentable assets before investing. Market: Large target market with a clear regulatory pathway for approval, with favorable reimbursement and pricing policies. Exit Potential: Sectors with VC/M&A or IPO activity, featuring profitable exits and multiple potential acquirers. Sustainability: During the due diligence process, sustainability risks are taken into account, and whenever identified, mitigation measures are proposed.